T C Lairmore
Overview
Explore the profile of T C Lairmore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
688
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lairmore T, Moley J
Scand J Surg
. 2005 Jan;
93(4):311-5.
PMID: 15658673
Neuroendocrine tumors of the pancreas are rare neoplasms that may arise sporadically or in association with a hereditary endocrine neoplasia syndrome. Effective management requires directed biochemical testing, careful choice of...
2.
Cohen M, Arslan N, Dehdashti F, Doherty G, Lairmore T, Brunt L, et al.
Surgery
. 2001 Dec;
130(6):941-6.
PMID: 11742321
Background: Thyroid tumors often exhibit increased metabolic activity, as evidenced by enhanced glucose uptake on positron emission tomography (PET) with use of (18)F-fluorodeoxyglucose (FDG). The incidence of new thyroid lesions...
3.
Brunt L, Moley J, Doherty G, Lairmore T, DeBenedetti M, Quasebarth M
Surgery
. 2001 Oct;
130(4):629-34; discussion 634-5.
PMID: 11602893
Background: Laparoscopic adrenalectomy (LA) has become the preferred method of removal of most adrenal neoplasms, but few studies have evaluated the functional outcomes of this approach. The purpose of this...
4.
Lairmore T, Chen V, DeBenedetti M, Gillanders W, Norton J, Doherty G
Ann Surg
. 2000 May;
231(6):909-18.
PMID: 10816635
Objective: To review the authors' 7-year experience with a surgical approach for pancreatic and duodenal neuroendocrine tumors (NETs) in patients with multiple endocrine neoplasia type 1 (MEN 1) designed to...
5.
Phay J, Moley J, Lairmore T
Semin Surg Oncol
. 2000 May;
18(4):324-32.
PMID: 10805954
Multiple endocrine neoplasia type 1 (MEN 1), and the multiple endocrine neoplasia type 2 syndromes (MEN 2A, MEN 2B, and familial non-MEN medullary thyroid carcinoma [FMTC]) encompass a wide range...
6.
Moley J, Lairmore T, Doherty G, Brunt L, DeBenedetti M
Surgery
. 1999 Oct;
126(4):673-7; discussion 677-9.
PMID: 10520914
Background: The recurrent laryngeal nerve (RLN) is vulnerable to injury in thyroid and parathyroid reoperations because of the presence of scar tissue and displacement of the nerve from its normal...
7.
Moley J, Lairmore T, Phay J
Curr Probl Surg
. 1999 Sep;
36(9):653-762.
PMID: 10491659
No abstract available.
8.
Mutch M, Dilley W, Sanjurjo F, DeBenedetti M, Doherty G, Wells Jr S, et al.
Hum Mutat
. 1999 Mar;
13(3):175-85.
PMID: 10090472
Multiple endocrine neoplasia type 1 (MEN 1) is a familial cancer syndrome characterized by parathyroid hyperplasia, pituitary adenomas, and neuroendocrine tumors of the pancreas and duodenum. In 1997, the MEN1...
9.
Lowney J, Frisella M, Lairmore T, Doherty G
Surgery
. 1998 Dec;
124(6):1043-8, discussion 1048-9.
PMID: 9854581
Background: Islet cell tumor (ICT) metastasis is one of the potentially lethal outcomes of multiple endocrine neoplasia type 1 (MEN 1). Management of ICT in patients with MEN 1 is...
10.
Yim J, Siegel B, DeBenedetti M, Norton J, Lairmore T, Doherty G
Surgery
. 1998 Dec;
124(6):1037-42.
PMID: 9854580
Background: Neuroendocrine tumors (NETs) are a potentially lethal component of multiple endocrine neoplasia type 1 (MEN 1). Somatostatin receptor scintigraphy (SRS) can be used to localize NETs and evaluate patients...